MCA
DNLI icon

Maryland Capital Advisors’s Denali Therapeutics DNLI Stock Holding History

Maryland Capital Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26 Buy
+1
New +$21 ﹤0.01% 1002

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Maryland Capital Advisors's DNLI Position: Q2 2026 in Review

Maryland Capital Advisors opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 1 share worth $26. The stake represents ﹤0.01% of the portfolio and ranks #1002 among its holdings.

292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Maryland Capital Advisors held 1 share of Denali Therapeutics worth $26 as of Q2 2026.
  • Denali Therapeutics was a new Maryland Capital Advisors position in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Maryland Capital Advisors's portfolio in Q2 2026, its #1002 holding.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Maryland Capital Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.